Systems, devices, and methods including infection-fighting and monitoring shunts
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-005/00
A61M-027/00
A61B-005/145
A61L-002/08
A61M-005/142
A61N-001/20
A61B-005/00
A61L-002/00
A61L-002/14
A61N-005/06
A61B-005/053
A61B-005/1459
A61N-001/372
A61N-005/02
A61B-005/1473
A61N-001/40
A61N-001/378
A61B-018/20
A61N-005/10
A61N-007/00
출원번호
US-0800792
(2010-05-21)
등록번호
US-8888731
(2014-11-18)
발명자
/ 주소
Dacey, Jr., Ralph G.
Hyde, Roderick A.
Ishikawa, Muriel Y.
Kare, Jordin T.
Leuthardt, Eric C.
Myhrvold, Nathan P.
Rivet, Dennis J.
Smith, Michael A.
Sweeney, Elizabeth A.
Tegreene, Clarence T.
Wood, Jr., Lowell L.
Wood, Victoria Y. H.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
2인용 특허 :
151
초록
Systems, devices, methods, and compositions are described for providing an actively controllable shunt configured to, for example, monitor, treat, or prevent an infection.
대표청구항▼
1. An implantable shunt system, comprising: a body structure having an outer surface and an inner surface defining one or more fluid-flow passageways configured to receive a cerebrospinal fluid of a biological subject; andone or more energy emitters configured to direct an energy stimulus to at leas
1. An implantable shunt system, comprising: a body structure having an outer surface and an inner surface defining one or more fluid-flow passageways configured to receive a cerebrospinal fluid of a biological subject; andone or more energy emitters configured to direct an energy stimulus to at least one of an interior and an exterior of at least one of the one or more fluid-flow passageways, the energy stimulus of a character and for a duration sufficient to induce programmed cell death of at least a portion of cells, without substantially inducing necrosis of at least a portion of cells, proximate at least one of the outer surface and the inner surface of the body structure. 2. The implantable shunt system of claim 1, wherein the body structure includes one or more proximal shunts, distal shunts, or flow-regulating devices, the one or more fluid-flow passageways extending through an interior of the one or more proximal shunts, distal shunts, or flow-regulating devices. 3. The implantable shunt system of claim 1, wherein the body structure includes an inlet and an outlet, at least one of the one or more fluid-flow passageways extending through the body structure between the inlet and outlet. 4. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable to an interior of one or more of the one or more fluid-flow passageways. 5. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable to an exterior of one or more of the one or more fluid-flow passageways. 6. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable, via one or more waveguides, to an interior of at least one of the one or more fluid-flow passageways. 7. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is configured to emit an energy stimulus from an interior of at least one of the one or more fluid-flow passageways to an exterior of at least one of the one or more fluid-flow passageways. 8. The implantable shunt system of claim 1, wherein at least a portion of a body structure defining the one or more fluid-flow passageways includes an optical material that permits the transmission of at least a portion of an emitted energy′ stimulus from an interior of at least one of the one or more fluid-flow passageways to an exterior of at least one of the one or more fluid-flow passageways. 9. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to emit an energy stimulus having one or more peak emission wavelengths in the x-ray, ultraviolet, visible, infrared, near infrared, terahertz, microwave, or radio frequency spectrum. 10. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is configured to deliver one or more charged particles. 11. The implantable shunt system of claim 1, wherein the one or more energy emitters include one or more lasers, laser diodes, light-emitting diodes, arc flashlamps, incandescent emitters, or continuous wave bulbs. 12. The implantable shunt system of claim 1, wherein the one or more energy emitters include one or more light-emitting diodes, quantum dots, organic light-emitting diodes, microcavity light-emitting diodes, or polymer light-emitting diodes. 13. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to provide a voltage across at least a portion of cells within a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways, the voltage of sufficient strength or duration so as to exceed a nominal dielectric strength of at least one cell plasma membrane. 14. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to provide a voltage across at least a portion of cells within a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways, the voltage of sufficient strength or duration so as to exceed a nominal dielectric strength of a cell plasma membrane without substantially interfering with a normal operation of the implantable shunt system. 15. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to sufficiently internally reflect at least a portion of an emitted energy stimulus to generate an evanescent electromagnetic field across one or more regions of the body structure. 16. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to sufficiently internally reflect at least a portion of an emitted energy stimulus to cause an evanescent electromagnetic field to emanate from at least a portion of the body structure. 17. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to internally reflect at least a portion of an emitted energy stimulus within an interior of at least one of the one or more fluid-flow passageways. 18. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to totally internally reflect at least a portion of an emitted energy stimulus propagated within an interior of at least one of the one or more fluid-flow passageways. 19. The implantable shunt system of claim 1, further comprising: a plurality of electromagnetic energy waveguides operably coupled to the at least one of the one or more energy emitters and configured to direct an emitted energy stimulus to one or more regions proximate at least one of the outer surface and the inner surface of the body structure. 20. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to provide a spatially patterned energy stimulus. 21. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver a spatially collimated energy stimulus. 22. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver a spatially focused energy stimulus. 23. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to provide a temporally patterned energy stimulus. 24. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver an energy stimulus of a character and for a duration sufficient to provide a spatially patterned energy stimulus to one or more regions proximate at least one of the outer surface and the inner surface of the body structure. 25. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to internally direct at least a portion of an emitted energy stimulus propagated within an interior of at least one of the one or more fluid-flow passageways. 26. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to laterally internally direct or longitudinally internally direct at least a portion of an emitted energy stimulus within an interior of at least one of the one or more fluid-flow passageways. 27. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct a first portion of an emitted energy stimulus along a substantially lateral direction in one or more regions of at least one of the one or more fluid-flow passageways and configured to direct a second portion of the emitted energy stimulus along a substantially longitudinal direction in one or more regions of at least one of the one or more fluid-flow passageways. 28. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct at least a portion of an emitted energy stimulus along a substantially lateral direction in a first region of at least one of the one or more fluid-flow passageways and configured to direct at least a portion of the emitted energy stimulus along a substantially lateral direction in a second region of the one or more fluid-flow passageways, the second region different from the first region. 29. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct at least a portion of an emitted energy stimulus along a substantially longitudinal direction in a first region of at least one of the one or more fluid-flow passageways and configured to direct at least a portion of the emitted energy stimulus along a substantially longitudinal direction in a second region of the one or more fluid-flow passageways, the second region different from the first region. 30. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to externally direct at least a portion of an emitted energy stimulus propagated within. 31. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to externally direct at least a portion of an emitted energy stimulus propagated within one or more regions proximate at least one of the outer surface and the inner surface of the body structure. 32. An in vivo method of treating an infectious agent, comprising: providing an energy stimulus for a time and amount sufficient to induce programmed cell death of an infectious agent, without substantially inducing necrosis of at least a portion of cells, within a cerebrospinal fluid of a mammal, the cerebrospinal fluid received within one or more fluid-flow passageways of an indwelling implant including one or more energy-emitting components energetically coupleable to an interior of the one or more fluid-flow passageways. 33. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing a sufficient amount of at least one of an x-ray, ultraviolet, visible, infrared, near infrared, terahertz, microwave, and radio frequency radiation. 34. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes delivering an effective dose of optical energy at which a cell preferentially undergoes apoptosis compared to necrosis. 35. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing an ultraviolet radiation of a character or duration to induce cell death by apoptosis. 36. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing a dose of an ultraviolet radiation based on a detected characteristic associated with the cerebrospinal fluid. 37. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing an electromagnetic energy stimulus of a character and for a sufficient time to induce apoptosis without substantially inducing necrosis of an infectious agent present in the cerebrospinal fluid. 38. The method of claim 32, further comprising: delivering an antimicrobial agent composition to a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways. 39. The method of claim 32, further comprising: delivering an antimicrobial agent composition to a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways at a dose sufficient to attenuate an activity of the infectious agent. 40. A method of inhibiting a microbial proliferation in the cerebrospinal fluid of a biological subject, comprising: selectively energizing one or more regions of at least one fluid-flow passageway of an indwelling implant cerebrospinal fluid management system for a time and amount sufficient to induce programmed cell death of a microbe via one or more energy-emitting components in optical communication with an interior of the least one fluid-flow passageway. 41. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 100 nanometers to about 400 nanometers. 42. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 100 nanometers to about 320 nanometers. 43. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 280 nanometers to about 320 nanometers. 44. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of the one or more energy emitters is less than about 80 milli-joules per square centimeter. 45. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of less than about 35 milli-joules per square centimeter. 46. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of less than about 15 milli-joules per square centimeter. 47. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an average energy density′ ranging from about less than about 15 milli-joules per square centimeter to about less than about 80 milli-joules per square centimeter. 48. The method of claim 40, further comprising: delivering an active agent composition to an interior of at least one fluid-flow passageway of an indwelling implant cerebrospinal fluid management system via one or more active agent assemblies in fluidic communication with the interior of the least one fluid-flow passageway.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (151)
Menon I. Aravindakshan,CAX ; Haberman Herbert F.,CAX, 33 Lipomelanin sunscreen composition.
Seeberger,Michael; Vanderlinde,Scott; Kalgren,James; Lindh,Par; Larsen Kelly,Kristine M.; Lanz,Mitchell; Thompson,Jeffrey M.; Dyjach,John A., Adaptive software configuration for a medical device.
Smith, Patrick J.; Jones, Jason A.; McGonagle, Kevin A., Apparatus and method for activation of a digital signal processor in an idle mode for interprocessor transfer of signal groups in a digital signal processing unit.
Snaper Alvin A. (2800 Cameo Cir. Las Vegas NV 89107) Gelbaum Bernard R. (127 Ruskin Rd. Buffalo NY 14226) Gelbaum Daniel (48 Bellevue San Rafael CA 94901), Bio-operable power source.
Panero,Stefania; Abbati,Gianluca; Renier,Davide; Crescenzi,Vittorio, Electrically conductive polymeric biomaterials, the process for their preparation and the use thereof in the biomedical and healthcare field.
Oksman Henry C. (140 Morris La. Scarsdale NY 10583) Eisner Joseph (219 E. 32nd St. New York NY 10016), Electrochemical contact lens disinfection and neutralization system.
Nova Michael P. ; Parandoosh Zahra ; Senyei Andrew E. ; Xiao Xiao-Yi ; David Gary S. ; Satoda Yozo ; Zhao Chanfeng ; Potash Hanan, Matrices with memories and uses thereof.
Wilk Peter J. (185 West End Ave. New York NY 10023) Tiefenbrun Jonathan (62 Country Rd. Mamaroneck NY 10543), Method and apparatus for catheter sterilization.
Frank R. Prosl ; Hans-Dietrich Polaschegg AT; Brian K. Estabrook ; Klaus Sodemann DE, Method and apparatus for overcoming infection in a tissue pocket surrounding an implanted device.
Khalil,Omar S.; Yeh,Shu jen; Kantor,Stanislaw; Hanna,Charles F.; Shain,Eric B., Method for optical measurements of tissue to determine disease state or concentration of an analyte.
Silver Jerry (Lyndhurst OH) Smith George M. (Cleveland OH) Jacobberger James W. (Chesterland OH), Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use o.
John T. Santini, Jr. ; Charles E. Hutchinson ; Scott A. Uhland ; Michael J. Cima ; Robert S. Langer ; Dennis Ausiello, Microfabricated devices for the delivery of molecules into a carrier fluid.
Santini, Jr., John T.; Sheppard, Jr., Norman F.; Young, Chung Chang; Langer, Robert S., Microfabricated devices for the storage and selective exposure of chemicals and devices.
Boni Lawrence T. ; Janoff Andrew S. ; Minchey Sharma R. ; Perkins Walter R. ; Swenson Christine E. ; Ahl Patrick L. ; Davis Thomas S., Pharmaceutical compositions containing interdigitation-fusion liposomes and gels.
Connelly,Patrick R.; Foster,Thomas H.; Weiner,Michael L.; Custer,Andrew W., Process for identifying cancerous and/or metastatic cells of a living organism.
Wong Tai-Ting (7th Fl. ; No. 320-3 ; Shin Pai Rd. ; Sec. 2 Taipei) Lee Liang-Shong (Taipei) Niu Gregory C. (Taipei TWX), Shunting device adopted in the intracranial shunting surgical operation for the treatment of hydrocephalus.
Brennan, Anthony B; Baney, Ronald H.; Carman, Michelle L.; Estes, Thomas G.; Feinberg, Adam W.; Wilson, Leslie H.; Schumacher, James F., Surface topographies for non-toxic bioadhesion control.
Currie, John F.; Paranjape, Makarand; Peck, Carl C.; White, Robert; Schneider, Thomas W., Systems and methods for monitoring health and delivering drugs transdermally.
Greenfeld Albert R. (31430 Glenbridge Rd. Westlake Village CA 91361) Reis Herbert (Thousand Oaks CA) Tittmann Bernhard R. (Thousand Oaks CA), Ultrasonic self-cleaning catheter system for indwelling drains and medication supply.
Pennell Phillip E. (Denver CO) Blackmore John M. (Redwood City CA) Allen Mark D. (Lakewood CO), Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same.
Kittrell Carter (Cambridge MA) Willett Robert L. (Billings MT) de los Santos-Pacheco Cynthia (Cambridge MA) Kenny Leo T. (New Bedford MA) Feld Michael S. (Waban MA), Visible fluorescence spectral diagnostic for laser angiosurgery.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.